PitchSend

Investor Presentaiton

Our India business grew at 12% CAGR (FY16 Gr:19%) REVENUES (Rs Cr) STRATEGIC FOCUS Deep focus on Chronic and Super-specialty therapies Strategic business development and M&A efforts ⚫ Differentiated assets in relevant therapies +12% 2,129 1,787 1,571 1,456 1,293 FY12 FY13 FY14 FY15 FY16 Successful integration of the brands acquired from UCB Improvement on the back of - • Focused sales & marketing efforts on mega brands • Improving new launch productivity • Scale-up in institutions sales

View entire presentation